Selection and Optimization of Hits from a High-Throughput Phenotypic Screen Against Trypanosoma Cruzi
Future Medicinal Chemistry2013Vol. 5(15), pp. 1733–1752
Citations Over TimeTop 12% of 2013 papers
Martine Keenan, Paul W. Alexander, Jason H. Chaplin, Michael J. Abbott, Hugo Diao, Zhisen Wang, Wayne M. Best, Catherine Perez, Scott Cornwall, Sarah Keatley, RC Andrew Thompson, Susan A. Charman, Karen L. White, Eileen Ryan, Gong Chen, Jean‐Robert Ioset, Thomas W von Geldern, Eric Chatelain
Abstract
High-throughput screening of novel compound collections has an important role to play in diversifying the trypanosomatid drug discovery portfolio. A new T. cruzi inhibitor series with good drug-like properties and promising in vivo efficacy has been identified through this process.
Related Papers
- → Analogues of Fenarimol Are Potent Inhibitors of Trypanosoma cruzi and Are Efficacious in a Murine Model of Chagas Disease(2012)68 cited
- → Evidence of Trypanosoma cruzi II infection in Colombian chagasic patients(2008)58 cited
- → Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease(2020)12 cited
- → The reception by French physicians of Chagas' discovery of Trypanosoma cruzi and American trypanosomiasis (1909-1925)(2009)3 cited
- → Discovery and Optimization\nof a Compound Series Active\nagainst <i>Trypanosoma cruzi</i>, the Causative Agent of\nChagas Disease(2020)